{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:55:32Z","timestamp":1787068532289,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.trim.2023.101976","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T02:28:58Z","timestamp":1704680938000},"page":"101976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts"],"prefix":"10.1016","volume":"82","author":[{"given":"O.W.","family":"Bredewold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"van Oeveren-Rietdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Florijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.I.","family":"Rotmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"van Zonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/TP.0000000000003350","article-title":"Thirty years of tacrolimus in clinical practice","volume":"105","author":"Ong","year":"2021","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2023.101976_bb0015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.trim.2023.101976_bb0020","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","article-title":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.trim.2023.101976_bb0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40620-017-0411-0","article-title":"Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism","volume":"30","author":"Schulte","year":"2017","journal-title":"J. Nephrol."},{"key":"10.1016\/j.trim.2023.101976_bb0030","doi-asserted-by":"crossref","unstructured":"de Graav, G.N., et al., A randomized controlled clinical trial comparing Belatacept with tacrolimus after De novo kidney transplantation. Transplantation, 2017. 101(10): p. 2571\u20132581.","DOI":"10.1097\/TP.0000000000001755"},{"issue":"11","key":"10.1016\/j.trim.2023.101976_bb0035","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient Calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function","volume":"17","author":"Adams","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.trim.2023.101976_bb0040","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"5","key":"10.1016\/j.trim.2023.101976_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","author":"Ojo","year":"2006","journal-title":"Transplantation"},{"issue":"9800","key":"10.1016\/j.trim.2023.101976_bb0050","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants","volume":"378","author":"Jardine","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.trim.2023.101976_bb0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrneph.2017.51","article-title":"The immunology of atherosclerosis","volume":"13","author":"Gistera","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0060","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.trim.2023.101976_bb0065","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri.2017.28","article-title":"Monocyte differentiation and antigen-presenting functions","volume":"17","author":"Jakubzick","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0070","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41598-020-61022-1","article-title":"Identification of novel human monocyte subsets and evidence for phenotypic groups defined by Interindividual variations of expression of adhesion molecules","volume":"10","author":"Merah-Mourah","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.trim.2023.101976_bb0075","first-page":"311","article-title":"Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (prospective Halle monocytes study)","volume":"60","author":"Hopfner","year":"2019","journal-title":"Hell. J. Cardiol."},{"issue":"6","key":"10.1016\/j.trim.2023.101976_bb0080","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/cvr\/cvaa234","article-title":"Human CD16+ monocytes promote a pro-atherosclerotic endothelial cell phenotype via CX3CR1-CX3CL1 interaction","volume":"117","author":"Roy-Chowdhury","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0085","doi-asserted-by":"crossref","first-page":"10236","DOI":"10.1038\/s41598-019-46724-5","article-title":"Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease","volume":"9","author":"Borges Bonan","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/eurheartj\/ehq371","article-title":"CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease","volume":"32","author":"Rogacev","year":"2011","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-6143.2007.02035.x","article-title":"Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients","volume":"8","author":"Ulrich","year":"2008","journal-title":"Am. J. Transplant."},{"issue":"26","key":"10.1016\/j.trim.2023.101976_bb0100","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.trim.2023.101976_bb0105","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra0902927","article-title":"Rejection of the kidney allograft","volume":"363","author":"Nankivell","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.trim.2023.101976_bb0110","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1073\/pnas.92.9.3893","article-title":"T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein","volume":"92","author":"Stemme","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19\u201320","key":"10.1016\/j.trim.2023.101976_bb0115","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.cca.2012.04.031","article-title":"Lymphocytes in atherosclerosis","volume":"413","author":"Wigren","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.trim.2023.101976_bb0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","article-title":"Abatacept mechanism of action: concordance with its clinical profile","volume":"8","author":"Herrero-Beaumont","year":"2012","journal-title":"Reumatol Clin"},{"issue":"5","key":"10.1016\/j.trim.2023.101976_bb0125","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.trim.2023.101976_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122198","article-title":"Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig","volume":"10","author":"Rochman","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.trim.2023.101976_bb0135","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from Calcineurin inhibitor to Belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100574","article-title":"Cardiovascular risk following conversion to Belatacept from a Calcineurin inhibitor in kidney transplant recipients: a randomized clinical trial","volume":"5","author":"Bredewold","year":"2023","journal-title":"Kidney Med"},{"issue":"6","key":"10.1016\/j.trim.2023.101976_bb0145","article-title":"Alemtuzumab as antirejection therapy: T cell repopulation and cytokine responsiveness","volume":"2","author":"Bouvy","year":"2016","journal-title":"Transplant. Direct"},{"issue":"11","key":"10.1016\/j.trim.2023.101976_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107708","article-title":"Type 2 diabetes mellitus metabolic control correlates with the phenotype of human monocytes and monocyte-derived macrophages","volume":"34","author":"Valtierra-Alvarado","year":"2020","journal-title":"J. Diabetes Complicat."},{"issue":"2","key":"10.1016\/j.trim.2023.101976_bb0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.trsl.2014.07.008","article-title":"Bezafibrate, a peroxisome proliferator-activated receptor \u03b1 agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes","volume":"165","author":"Terasawa","year":"2015","journal-title":"Transl. Res."},{"issue":"9","key":"10.1016\/j.trim.2023.101976_bb0160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/apm.12419","article-title":"Elevated levels of peripheral blood CD14(bright) CD16+ and CD14(dim) CD16+ monocytes may contribute to the development of retinopathy in patients with juvenile onset type 1 diabetes","volume":"123","author":"Ryba-Stanis\u0142awowska","year":"2015","journal-title":"APMIS"},{"issue":"2","key":"10.1016\/j.trim.2023.101976_bb0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7150\/ijbs.15659","article-title":"Increase in peripheral blood intermediate monocytes is associated with the development of recent-onset type 1 diabetes mellitus in children","volume":"13","author":"Ren","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0170","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cyto.2012.03.010","article-title":"Expansion of CD14+CD16+ monocytes producing TNF-\u03b1 in complication-free diabetes type 1 juvenile onset patients","volume":"60","author":"My\u015bliwska","year":"2012","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.trim.2023.101976_bb0175","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF","volume":"168","author":"Belge","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.trim.2023.101976_bb0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ndt\/gfu315","article-title":"Immunosuppression and monocyte subsets","volume":"30","author":"Rogacev","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"17","key":"10.1016\/j.trim.2023.101976_bb0185","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2013-02-484188","article-title":"Transcription and enhancer profiling in human monocyte subsets","volume":"123","author":"Schmidl","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.trim.2023.101976_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121750","article-title":"Transcriptome analysis in patients with chronic kidney disease on hemodialysis disclosing a key role for CD16+CX3CR1+ monocytes","volume":"10","author":"Schepers","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0195","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4049\/jimmunol.1001866","article-title":"Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity","volume":"186","author":"Merino","year":"2011","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0200","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/db09-0659","article-title":"CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes","volume":"59","author":"Komura","year":"2010","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.trim.2023.101976_bb0205","first-page":"1198","article-title":"Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease","volume":"108","author":"Dopheide","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.trim.2023.101976_bb0210","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2017-03-771261","article-title":"Circulatory and maturation kinetics of human monocyte subsets in vivo","volume":"130","author":"Tak","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.trim.2023.101976_bb0215","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2012-03-418681","article-title":"Pivotal role of M-DC8+ monocytes from viremic HIV-infected patients in TNF\u03b1 overproduction in response to microbial products","volume":"120","author":"Dutertre","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101976_bb0220","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3389\/fimmu.2019.02052","article-title":"6-Sulfo LacNAc (Slan) as a marker for non-classical monocytes","volume":"10","author":"Hofer","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.trim.2023.101976_bb0225","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1182\/blood-2011-01-326827","article-title":"SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset","volume":"118","author":"Zawada","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trim.2023.101976_bb0230","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3389\/fimmu.2019.00948","article-title":"Current concepts on 6-sulfo LacNAc expressing monocytes (slanMo)","volume":"10","author":"Ahmad","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.trim.2023.101976_bb0235","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0198-8859(00)00152-X","article-title":"Switch from cyclosporine a to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses","volume":"61","author":"Weimer","year":"2000","journal-title":"Hum. Immunol."},{"issue":"5","key":"10.1016\/j.trim.2023.101976_bb0240","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/TP.0b013e318205b3c1","article-title":"Monocyte-secreted inflammatory cytokines are associated with transplant glomerulopathy in renal allograft recipients","volume":"91","author":"De Serres","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2023.101976_bb0245","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41232-017-0054-5","article-title":"Effects of CTLA4-Ig on human monocytes","volume":"37","author":"Tono","year":"2017","journal-title":"Inflamm Regen"},{"issue":"4","key":"10.1016\/j.trim.2023.101976_bb0250","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1186\/cc7969","article-title":"Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis","volume":"13","author":"Poehlmann","year":"2009","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/j.trim.2023.101976_bb0255","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.33418","article-title":"The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population","volume":"64","author":"Rossol","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.trim.2023.101976_bb0260","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.transproceed.2020.02.176","article-title":"Elevated monocyte count and loss of renal function in renal transplant patients","volume":"52","author":"Buberci","year":"2020","journal-title":"Transplant. Proc."},{"issue":"12","key":"10.1016\/j.trim.2023.101976_bb0265","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.4049\/jimmunol.0902194","article-title":"An innate response to allogeneic nonself mediated by monocytes","volume":"183","author":"Zecher","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.trim.2023.101976_bb0270","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI74370","article-title":"Non-self recognition by monocytes initiates allograft rejection","volume":"124","author":"Oberbarnscheidt","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.trim.2023.101976_bb0275","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.trim.2023.101976_bb0280","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1111\/ajt.13853","article-title":"Comparison of utilization and clinical outcomes for Belatacept- and tacrolimus-based immunosuppression in renal transplant recipients","volume":"16","author":"Wen","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2023.101976_bb0285","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.transproceed.2010.08.037","article-title":"High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment","volume":"42","author":"Furuzawa-Carballeda","year":"2010","journal-title":"Transplant. Proc."},{"issue":"2","key":"10.1016\/j.trim.2023.101976_bb0290","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cei.13296","article-title":"Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years","volume":"197","author":"Furuzawa-Carballeda","year":"2019","journal-title":"Clin. Exp. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423001934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327423001934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:04:41Z","timestamp":1760810681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327423001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":58,"alternative-id":["S0966327423001934"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2023.101976","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2023.101976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101976"}}